[{"id":"6875ca53-6d3a-4295-900b-d9b68a43e3c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989946","created_at":"2023-12-21T18:18:35.344Z","updated_at":"2025-02-25T14:16:15.460Z","phase":"Phase 1/2","brief_title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","source_id_and_acronym":"NCT04989946","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Libtayo (cemiplimab-rwlc) • Firmagon (degarelix) • fianlimab (REGN3767) • MVI-118"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-07"},{"id":"cd09087f-472f-402d-bf84-051c8aeafa99","acronym":"","url":"https://clinicaltrials.gov/study/NCT02411786","created_at":"2021-01-18T11:31:15.955Z","updated_at":"2024-07-02T16:36:35.053Z","phase":"Phase 1","brief_title":"A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF","source_id_and_acronym":"NCT02411786","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CD8 • CSF2","pipe":"","alterations":" ","tags":["CD8 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MVI-118"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/24/2015","start_date":" 08/24/2015","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 11/28/2020","study_completion_date":" 11/28/2020","last_update_posted":"2021-02-04"}]